# VIENCE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vience

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.vience.io
- Latest round: Seed (Jan 16, 2024)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2022, VIENCE operates as a bioinformatics company that provides cloud-based scientific analysis and medical diagnosis using artificial intelligence technology. In December 2023, VIENCE raised KRW 200 million in seed funding from CNTTech and DB Capital. As of January 2024, the company is led by its CEO Jeong Won-gi. 

VIENCE products offering includes VIENCE CANVAS, VIENCE PATHOVIEW, and VIENCE NEUROVIEW. These products are designed to streamline data analysis processes across various domains. VIENCE CANVAS stands as a visual programming platform that allows users to leverage technology through simple interactions, enabling the construction of robust data analysis workflows. Meanwhile, VIENCE PATHOVIEW and VIENCE NEUROVIEW cater to specific domains, ensuring tailored and optimized solutions for pathology and neurology research.

## Funding rounds

- Seed, Jan 16, 2024 — CNTTech, DB Capital

## Investors

- CNTTech — Seed
- DB Capital (https://capitalatlas.ai/funds/db-capital) — Seed